This could be the new Treatment developed in Mexico to neutralize COVID
To stop anyone from suffering or dying as a consequence of animal envenoming
OUR MISSION
We believe that no one should suffer or die as a consequence of animal envenoming. For this reason, we have developed a unique and original platform to make safe, effective, and non-cold chain dependent antivenoms available at a fair price.
We are eager to be part of the solution. We work close to patients along with the medical community, governments, and many international organizations and institutions in order to improve the access to antivenoms and the care for people affected by animal envenoming.
We currently distribute and commercialize our products mainly in Africa and Middle East and we are developing new antivenoms for other regions.
We perform our mission passionately and committed to the integrity wherever we operate. We reflect these values in our products, services, and communication while interacting with people.
Our strategy and products are aligned with the WHO plan to reduce the effects of animal envenoming.
OUR PRODUCTS
At Inosan Biopharma we develop and distribute the latest generation antivenoms that meet the highest manufacturing standards
Broad regional coverage of medically important species
Highly purified
High neutralizing capacity with low total protein content
No preservatives
Injectable lyophilizates
InoserpTM
PAN-AFRICA
Is a polyvalent equine antivenom specifically indicated for the treatment of sub-Saharan African snake bites. It is a sterile, highly purified lyophilized preparation of equine F(ab´)2 immunoglobulin fragments neutralizing with high specificity the venoms of the following species: Viperidae: Echis ocellatus, Echis leucogaster, Echis pyramidum, Bitis arietans, Bitis rhinoceros, Bitis nasicornis, Bitis gabonica; and Elapidae: Dendroaspis polylepis, Dendroaspis viridis, Dendroaspis angusticeps, Dendroaspis jamesoni, Naja nigricollis, Naja melanoleuca, Naja haje, Naja pallida, Naja nubiae, Naja katiensis and Naja senegalensis.
Is a polyvalent equine antivenom specifically indicated for the treatment of Middle East and North African scorpion stings. It is a sterile, highly purified lyophilized preparation of equine F(ab´)2 immunoglobulin fragments neutralizing with high specificity the venoms of the following species: Androctonus australis, Androctonus mauritanicus, Androctonus crassicauda, Androctonus amourexi, Androctonus bicolor, Buthus occitanus, Buthus mardochei, Leiurus quinquestriatus quinquestriatus, Leiurus quinquestriatus hebraeus, Buthus Tunetanus.
Technology driven solutions for the present and constantly evolving for the future.
At Inosan Biopharma, we have transformed antiserum to very pure antigen-binding immunoglobulin fragments with high neutralizing potency in full compliance with international GMPs requirements.
THE TEAM
Juan López de Silanes Blanco
CEO & Founder
Juan López de Silanes y Pérez
Chairman of the board & Founder
Beatriz López de Silanes Blanco
General Counsel & Chief
Compliance Officer
An independent family company. We care for people, especially those affected by animal envenoming all around the world.
Anne Walter
Regulatory Affairs Director
Jean Bernard Delbarre
Global Programs Director
Raúl Soria
VP & COO
Always close to your community sharing our knowledge and training the future experts
Snakebites are ‘neglected’ health crisis in Africa
Snakebites kill tens of thousands of Africans a year. Now, an antivenom shortage is spurring global experts to collaborate on treatment and prevention.
Snakebites are ‘neglected’ health crisis in Africa
Snakebites kill tens of thousands of Africans a year. Now, an antivenom shortage is spurring global experts to collaborate on treatment and prevention.
With at least 600,000 people worldwide killed or permanently disabled each year, snakebites are the biggest public health crisis that no one has heard of
